2m 2m 2m 2m 2m 2m - S&P 600$1,709.07
2m
- $364.3BMarket Cap
- 63.69%1-Year Change
- Drug Manufacturers - GeneralIndustry
Merck (MRK)
Key Performance
More- Earnings Score: 44
- Momentum Score: 67
- True Yield: 41
- Financial Health Score: 8
Latest Research & News
Is Merck's Stock Still a Good Buy at $150?
Merck's stock has surged nearly 40% in 2026, driven by strong Keytruda revenue including its new subcutaneous formulation Keytruda Qlex. However, the analyst recommends holding off on buying at current levels due to upcoming patent expirations in 2028 and uncertain revenue outlook, despite the stock trading at a modest discount to the S&P 500 average P/E multiple.
11/16/2026, 2:20 PM • The Motley Fool
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.
11/16/2026, 1:00 PM • GlobeNewswire
Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB?
The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) and iShares Biotechnology ETF (IBB). PPH focuses on 26 large, established drugmakers with lower volatility, higher dividend yield (1.8%), and lower expense ratio (0.36%). IBB offers broader diversification with 243 holdings but higher volatility and minimal dividend yield (0.2%). The author recommends PPH for long-term investors seeking stability and income, particularly given the major pharmaceutical companies' acquisition activity in biotech.
11/15/2026, 2:16 PM • The Motley Fool
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
11/15/2026, 1:19 PM • The Motley Fool
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
State Street's XPH (SPDR S&P Pharmaceuticals ETF) is recommended over Invesco's PBE (Biotechnology & Genome ETF) for long-term investors due to its lower expense ratio (0.35% vs 0.59%), broader diversification with 61 holdings, lower beta, and better recent 1-year performance (38.6% vs 33.2%). While PBE offers a higher dividend yield (1.3% vs 0.4%), XPH's exposure to pharmaceutical acquisitions and lower costs make it more suitable for most long-term investors.
11/15/2026, 11:51 AM • The Motley Fool
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.
11/14/2026, 11:12 AM • The Motley Fool
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
11/13/2026, 5:42 PM • The Motley Fool
Where These 4 Sector ETFs Stand Heading Into Year-End
As 2026 winds down, the article analyzes four key sector ETFs heading into 2027. Technology stocks have pulled back 14% from October highs after AI companies missed earnings, but the sector remains reasonably valued. Financial stocks are mixed, with insurance outperforming while banks struggle amid tepid loan demand. Energy stocks surged 40% YTD on oil prices but face headwinds as crude may have peaked around $90/barrel. Healthcare stocks are up 21% but appear slightly overvalued at current levels.
11/13/2026, 10:43 AM • The Motley Fool
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
11/10/2026, 11:00 AM • GlobeNewswire
The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.
11/10/2026, 10:00 AM • GlobeNewswire
BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.
11/09/2026, 5:00 AM • The Motley Fool
Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
Eli Lilly raised its 2026 revenue guidance to $91-92 billion from $85-87 billion, driven by strong GLP-1 drug sales including Mounjaro and Zepbound. Despite a 57% stock run-up and expensive 47x P/E valuation, the author argues the stock remains a buy due to massive untapped market potential for GLP-1 drugs across obesity, cardiovascular disease, addiction treatment, and potentially anti-aging applications.
11/07/2026, 1:30 PM • The Motley Fool
Evaxion announced new phase 2 biomarker data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, demonstrating potent neoantigen-specific T-cell responses and validating the predictive performance of its AI-Immunologyâ„¢ platform. The data showed 89% vaccine target precision with sustained clinical responses at three-year follow-up, including a 75% objective response rate at two years.
11/06/2026, 11:00 AM • GlobeNewswire
Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.
11/06/2026, 10:00 AM • GlobeNewswire
Moderna Just Gave Investors Yet Another Thing to Cheer About
Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.
11/06/2026, 9:48 AM • The Motley Fool
Peers
Statistics
MoreInformation as of 11/13/2026
Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Key Executives
- Robert Davis
- Dean Y. Li
- Caroline Litchfield
- Betty D. Larson
- Jennifer L. Zachary
Current Ownership Distribution
- Institutions37.6B (76.93%)
- Mutual Funds11.3B (23.05%)
- Insiders5.6M (0.01%)
- Other0 (0.00%)